|Day Low/High||78.02 / 80.08|
|52 Wk Low/High||75.62 / 107.25|
- FDA reviewed the submission under the Real-Time Oncology Review pilot program
MC10, Inc., a healthcare technology company specializing in wearable digital health sensors, and AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, announced today that the companies are working together on clinical trials designed to...
NORTH CHICAGO, Ill., May 14, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced that it has resolved U.
NORTH CHICAGO, Ill., May 14, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the UBS Global Healthcare Conference on Tuesday, May 21, 2019.
NORTH CHICAGO, Ill., May 7, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Bank of America Merrill Lynch Healthcare Conference on Wednesday, May 15, 2019.
- Approval based on results from clinical studies showing high rates of skin clearance at 16 weeks; this clearance was durable at one year with every 12-week dosing[1-4]
- Presentations include updates on ABBV-951, a subcutaneous infusion therapy for Parkinson's disease (PD), and elezanumab, a monoclonal antibody directed against repulsive guidance molecule A (RGMa) in multiple sclerosis (MS), among other data to be presented
AbbVie climbs after beating first-quarter estimates and raising full-year guidance.
As we have seen so far, in terms of market reaction, there is great reward at the point of sale in beating expectations.
- Reports First-Quarter Diluted EPS of $1.65 on a GAAP Basis; Adjusted Diluted EPS of $2.14 Reflects Growth of 14.4 Percent
U.S. stock futures trade mixed on Thursday; Amazon, Intel and Comcast report earnings; Microsoft jumps as third-quarter earnings beat analysts' expectations; Facebook sets aside $3 billion for expected fine from Federal Trade Commission.
- Approval based on clinical trials showing people treated with SKYRIZI™ (risankizumab-rzaa) every 12 weeks - four doses a year after two initial doses - achieved high levels of durable skin clearance at 16 weeks and maintained this response at one year[1-3]
SKYRIZI™(risankizumab) is a novel, humanized immunoglobulin monoclonal antibody designed to selectively inhibit IL-23 by binding to its p19 subunit to treat moderate to severe plaque psoriasis 1 .
Screening Goldman Sachs' list of the top 20 stocks to see which ones are the best technical opportunities.
Jim Cramer says this positive start will be hard to sustain this earnings season. He's got your game plan for next week.
Jim Cramer weighs in on Square, Cabot Oil & Gas, AbbVie, Philip Morris International, Bunge, Greenbrier Companies, LCI Industries and more.
NORTH CHICAGO, Ill., April 3, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will announce its first-quarter 2019 financial results on Thursday, April 25 before the market opens.
-This marks the first regulatory approval globally for SKYRIZI™ (risankizumab)
NORTH CHICAGO, Ill., March 19, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced the U.
- The Phase 3 CLL14 trial of venetoclax in combination with obinutuzumab is the first randomized clinical trial to examine a chemotherapy-free treatment given for a fixed duration in previously-untreated patients with chronic lymphocytic leukemia (CLL) and comorbidities
It's no secret why the list of S&P 500 'dividend aristocrats' is a who's-who of great Wall Street brands. Here's what makes them so special.
NORTH CHICAGO, Ill., March 1, 2019 /PRNewswire/ -- AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, will participate in the Barclays Global Healthcare Conference on Wednesday, March 13, 2019.
- CHMP positive opinion, supported by data from the pivotal Phase 3 program evaluating more than 2,000 patients with moderate to severe plaque psoriasis, will now be reviewed by the European Commission(1-3)
Experts offer their top stock ideas in oncology detection and treatment.
The most recent short interest data has been released for the 02/15/2019 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the S&P 500 by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.
Jim Cramer says if you focus on what's going right, you'll sleep better and do a lot better with your money, too.
Jim Cramer weighs in on Waste Management, Weight Watchers, Centene, Aurinia Pharmaceuticals, Activision Blizzard, AbbVie, Cronos Group and more.
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.